Epilepsy Drugs Market Size
| Study Period | 2018 - 2028 |
| Market Size (2024) | USD 9.51 Billion |
| Market Size (2029) | USD 11.96 Billion |
| CAGR (2024 - 2029) | 4.69 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Epilepsy Drugs Market Analysis
The Epilepsy Drugs Market size is estimated at USD 9.51 billion in 2024, and is expected to reach USD 11.96 billion by 2029, growing at a CAGR of 5% during the forecast period (2024-2029).
The epilepsy drug market is driven by the rising prevalence of epilepsy globally, which contributes to a growing patient population, creating a higher demand for epilepsy-related medications and treatments. Moreover, ongoing research and development have led to the discovery of new and more effective anti-epileptic drugs and therapies, expanding the treatment options available.
The growing burden of epilepsy is expected to create the demand for effective anti-epileptic drugs, which is likely to contribute to market growth over the forecast period. For instance, according to the World Health Organization's February 2023 report, epilepsy affected approximately 50 million people globally, making it one of the most prevalent neurological disorders worldwide. Similarly, according to GOV.UK data published in January 2024, a total of 191,623 drug seizures occurred in England and Wales in the year ending March 2023, a 1% increase compared to the previous year (188,929). Such a high burden of epilepsy creates the need for treatment and, thus, drives the market's growth.
Furthermore, supportive policies, research grants, and government initiatives aimed at epilepsy awareness, research, and treatment can stimulate growth in the epilepsy market. For instance, in November 2023, the Epilepsy Foundation launched a public awareness campaign called 'Change Epilepsy Story' aimed at combating the stigma surrounding epilepsy. By encouraging people with epilepsy and their caregivers to share their experiences, including diagnosis and treatment, the campaign hopes to raise awareness and promote understanding. This type of initiative is expected to fuel growth in the epilepsy market.
Additionally, the increasing launch of drugs for the treatment of epilepsy by market players at affordable prices is also contributing to the growth of the market. For instance, in October 2023, Catalyst Pharmaceuticals Inc. announced that it had participated in the 11th Annual Epilepsy Awareness Day & Education Expo to raise awareness and education among the epilepsy community in partnership with Sofie's Journey and Epilepsy Alliance of America, which hosted the largest gathering of patients, families, and physicians in the United States. Such initiatives are expected to create awareness of epilepsy, thereby boosting market growth.
Thus, owing to the abovementioned factors, the market's growth is expected to accelerate over the coming years. However, side effects associated with drugs and the recent expiration of patents on major drugs may impede the market's growth.
Epilepsy Drugs Market Trends
Second Generation Anti-epileptics is Expected to Hold a Significant Market Share Over the Forecast Period
Second-generation anti-epileptic drugs (AEDs) refer to a class of medications that have been developed as newer alternatives to traditional or first-generation AEDs. These drugs are designed to offer improved efficacy, safety, and tolerability for the management of epilepsy. The growth of the second-generation anti-epileptics segment is driven by several factors, such as better efficacy and tolerability, fewer and less severe side effects, innovation, and patent expiration.
The growing prevalence of epilepsy globally contributes to a higher demand for effective and well-tolerated anti-epileptic medications, driving the growth of this segment. Furthermore, according to the article published in Frontier in Epidemiology in August 2023, the incidence rate of epilepsy was estimated at around 50 to 60 per 100,000 people each year, and up to 8% of people had at least one seizure in their lifetime. It is consistently higher than the rate of epilepsy in Australia. Thus, the growing prevalence of epilepsy globally contributes to a higher demand for second-generation anti-epileptic drugs, thereby boosting the segment’s growth.
Second-generation AEDs often demonstrate better efficacy and tolerability profiles compared to their predecessors, leading to increased adoption by healthcare providers. For instance, according to a study published in the MDPI Journal in February 2023, Gabapentin is recommended against partial epilepsy with/without secondary generalization and can be used in patients over three years of age. In addition, it may be used for neuropathic pain, restless legs syndrome, fibromyalgia, trigeminal neuralgia, multiple sclerosis, headache, anxiety, and postoperative pain. Thus, they have better efficacy against epilepsy and also have efficacy in treating other neurological or psychiatric conditions, broadening their market impact beyond epilepsy, thereby boosting segment growth.
Besides, market players are also acquiring other firms to expand their product portfolio. For instance, in January 2022, UCB acquired Zogenix for USD 1.9 billion to bolster its epilepsy portfolio by adding Fintepla (fenfluramine). It is a marketed drug for treating seizures associated with Dravet syndrome, a rare form of childhood epilepsy. This deal continues to expand UCB's extensive therapeutic offering in the epilepsy market, having gained a new product for patients with rare and difficult-to-treat pediatric orphan epilepsy syndromes.
Hence, owing to the new product launches and acceptance of second-generation epilepsy drugs, the segment is expected to grow over the forecast period.
North America is Expected to Hold Significant Share over the Forecast Period
North America is expected to show significant growth over the forecast period owing to the increasing burden of epilepsy coupled with the market players' strategic initiatives, awareness campaigns, and launches of new products. In November 2022, a press release by the CDC stated that epilepsy affected about 3.4 million Americans. About one out of 10 people may suffer from a seizure during their lifetime. There are over 260 epilepsy centers in the United States. Healthcare providers at these centers specialize in managing epilepsy and provide expert care to children and adults. Thus, the prevalence of epilepsy in the region is expected to increase the demand for its treatment and, thus, increase the market growth.
The approval of drugs for different age populations is also boosting the market's growth. For instance, in November 2023, Jazz Pharmaceuticals Canada Inc. announced that Epidiolex (cannabidiol oral solution) had been approved by Health Canada as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients two years of age and older.
Furthermore, various organizations have initiated research on epilepsy drugs, which is likely to contribute to the growth of the market. For instance, in October 2022, Avicanna Inc. expanded its research collaboration in epilepsy with a new collaboration with the University of Toronto. It is to explore the efficacy of Avicanna's proprietary formulations in pre-clinical models for epilepsy.
Thus, the market is expected to grow over the forecast period due to the rising burden of epilepsy, increasing research and development activities, and product launches by the market players.
Epilepsy Drugs Industry Overview
The market studied is a consolidated market owing to the presence of a few major market players. Therefore, most key players focus on expanding their businesses to increase their market share. They are also adopting specific strategies, such as new product development, mergers, and acquisitions. Some players operating in the market are Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, Pfizer Inc., Sanofi SA, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, and UCB SA.
Epilepsy Drugs Market Leaders
-
Abbott Laboratories
-
GlaxoSmithKline PLC
-
Johnson & Johnson Health Care Systems Inc.
-
Novartis AG
-
UCB S.A.
*Disclaimer: Major Players sorted in no particular order
Epilepsy Drugs Market News
- January 2024: Eisai Co. Ltd received marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of Fycompa (perampanel), its in-house discovered anti-epileptic drug (AED), in Japan as an alternative therapy when oral administration is temporarily not possible.
- October 2023: Xenon Pharmaceuticals announced results from the Phase IIb X-TOLE study, which showed that an investigational potassium channel opener XEN1101 could safely reduce seizure burden in adults with focal epilepsy.
Epilepsy Drugs Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumption and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the New Drug Approvals over the Past Few Years
4.2.2 Increase in the Cases of Epilepsy
4.3 Market Restraints
4.3.1 Side Effects Associated With the Drugs
4.3.2 Recent Patent Expiration of Major Brands
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Drugs
5.1.1 First Generation Anti-epileptics
5.1.2 Second Generation Anti-epileptics
5.1.3 Third Generation Anti-epileptics
5.2 By Distribution Channel
5.2.1 Hospital Pharmacy
5.2.2 Retail Pharmacies
5.2.3 Other Distribution Channels
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 GlaxoSmithKline PLC
6.1.3 Johnson & Johnson
6.1.4 Novartis AG
6.1.5 Pfizer Inc.
6.1.6 Sanofi SA
6.1.7 Takeda Pharmaceutical Company Limited
6.1.8 Sunovion Pharmaceuticals Inc.
6.1.9 UCB SA
6.1.10 Sun Pharmaceutical Industries Limited
6.1.11 GW Pharmaceuticals PLC
6.1.12 H. Lundbeck A/S
6.1.13 Alkem Labs
6.1.14 Eisai Co. Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Epilepsy Drugs Industry Segmentation
As per the scope of this report, epilepsy is a central nervous system (neurological) disorder when brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness. Epilepsy drugs do not cure epilepsy but help to control seizures.
The epilepsy drugs market is segmented by drugs, distribution channels, and geography. By drugs, the market is segmented as first-generation anti-epileptics, second-generation anti-epileptics, and third-generation anti-epileptics. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and other distribution channels. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East And Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD) for the above segments.
| By Drugs | |
| First Generation Anti-epileptics | |
| Second Generation Anti-epileptics | |
| Third Generation Anti-epileptics |
| By Distribution Channel | |
| Hospital Pharmacy | |
| Retail Pharmacies | |
| Other Distribution Channels |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Epilepsy Drugs Market Research FAQs
How big is the Epilepsy Drugs Market?
The Epilepsy Drugs Market size is expected to reach USD 9.51 billion in 2024 and grow at a CAGR of 4.69% to reach USD 11.96 billion by 2029.
What is the current Epilepsy Drugs Market size?
In 2024, the Epilepsy Drugs Market size is expected to reach USD 9.51 billion.
Who are the key players in Epilepsy Drugs Market?
Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson Health Care Systems Inc., Novartis AG and UCB S.A. are the major companies operating in the Epilepsy Drugs Market.
Which is the fastest growing region in Epilepsy Drugs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2028).
Which region has the biggest share in Epilepsy Drugs Market?
In 2023, the North America accounts for the largest market share in Epilepsy Drugs Market.
What years does this Epilepsy Drugs Market cover, and what was the market size in 2023?
In 2023, the Epilepsy Drugs Market size was estimated at USD 9.06 billion. The report covers the Epilepsy Drugs Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Epilepsy Drugs Market size for years: 2024, 2025, 2026, 2027 and 2028.
Epilepsy Drugs Industry Report
Statistics for the 2024 Epilepsy Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Epilepsy Drugs analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Epilepsy Drugs Market Report Snapshots
